Letter to the Editor regarding: Medicaid prescription limits and their implications for naloxone accessibility (by Roberts et al., 2021)

por Talbert, Jeffery, Bohler, Robert, Frazier, Lisa, El-Bassel, Nabila, Freeman, Patricia R.
Publicado 2021

State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements

por Silwal, Anita, Talbert, Jeffery, Bohler, Robert M., Kelsch, Jordan, Cook, Christopher, Blevins, Derek, Gallivan, Molly, Hunt, Timothy, Hatcher, Sarah M., Thomas, Cindy Parks, Williams, Soncere, Fanucchi, Laura, Lofwall, Michelle R.
Publicado 2023

The policy landscape for naloxone distribution in four states highly impacted by fatal opioid overdoses

por Bohler, Robert M., Freeman, Patricia R., Villani, Jennifer, Hunt, Tim, Linas, Beth S., Walley, Alexander Y., Green, Traci C., Lofwall, Michelle R., Bridden, Carly, Frazier, Lisa A., Fanucchi, Laura C., Talbert, Jeffery C., Chandler, Redonna
Publicado 2022